ClinicalTrials.gg
CompletedNCT01814137BOOST®Updated Mar 21, 2017Results posted

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

A Phase 3 interventional study of insulin degludec/insulin aspart and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 40 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
61st of 70
40 · median 384
Started
2013
with 7 others
Phase 3
49 of 70
2 open now
Registered
33rd of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 61st largest by enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 33rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of the trial is to compare efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) + insulin aspart (IAsp) once daily (OD) versus basal bolus with insulin degludec (IDeg) OD + IAsp three times a day (TID) in controlling glycaemia by evaluating glycosylated haemoglobin (HbA1c). The trial is an extension to trial NN5401-3941 (NCT01680341).

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 40 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • equal to or above 7.0% measured after 26 weeks of treatment in NN5401-3941 (NCT01680341), by central laboratory

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled or untreated severe hypertension defined as systolic blood pressure equal to or above 180 mmHg and/or diastolic blood pressure equal to or above 100 mmHg
  • Impaired liver function, defined as (ALAT) or aspartate aminotransferase (ASAT) equal to or above 2.5 times
  • Impaired renal function defined as serum-creatinine equal to or above 125 micromol/L (equal to or above 1.4 mg/dL) for males and equal to or above 110 micromol/L (equal to or above 1.3 mg/dL) for females
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    IDegAsp BID + IAsp OD

    Drug: insulin degludec/insulin aspart · Drug: insulin aspart

  • Experimental
    IDeg OD + IAsp TID

    Drug: insulin degludec · Drug: insulin aspart

Interventions

  • Druginsulin degludec/insulin aspart

    Drug pages: Insulin degludec · Insulin Aspart

    For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).

  • For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).

  • For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.

  • For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin)

    Change from baseline in HbA1c after 26 weeks of treatment

    Time frame: Week 0, week 26

Secondary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    A treatment emergent adverse event was defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last dose of the trial product.

    Time frame: During 26 weeks of treatment

  2. Number of Treatment Emergent Hypoglycaemic Episodes

    Confirmed hypoglycaemic episodes were defined as episodes that are either: * severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or * biochemically confirmed by a PG value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.

    Time frame: During 26 weeks of treatment

  3. Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes

    Hypoglycaemic episodes were defined as nocturnal if the time of onset was between 00:01 and 05:59 hours inclusive. Confirmed hypoglycaemic episodes were defined as severe hypoglycaemic episodes and/or a measured PG below 3.1 mmol/L (below 56 mg/dL).

    Time frame: During 26 weeks of treatment

  4. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline in FPG after 26 weeks of treatment. FPG was analysed on blood samples from fasting subjects which were analysed centrally.

    Time frame: Week 0, week 26

08

Results

Posted Nov 13, 2015
Limitations and caveats
Due to the highly selected trial population randomised in this trial (N=40), the results should be interpreted with caution.

Participant flow

The trial was conducted at 20 sites in 4 countries as follows: Germany: 1 site; Malaysia: 2 sites; Turkey: 1 site; United States: 16 sites. The subjects in this trial were to continue from trial NN5401-3941 (NCT01680341).

Participant flow — Overall Study
MilestoneIDegAsp BID + IAsp ODIDeg OD + IAsp TID
Started2020
Completed1515
Not completed55
Withdrew: Adverse event01
Withdrew: Withdrawal by subject22
Withdrew: Physician decision11
Withdrew: Unclassified21

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin)

Change from baseline in HbA1c after 26 weeks of treatment

Time frame:
Week 0, week 26
Reported as:
Least squares mean · percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
percentage of glycosylated haemoglobinIDegAsp BID + IAsp ODIDeg OD + IAsp TID
Change From Baseline in HbA1c (Glycosylated Haemoglobin)0.05 ± 0.20-0.49 ± 0.19
SecondaryIncidence of Treatment Emergent Adverse Events (TEAEs)

A treatment emergent adverse event was defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last dose of the trial product.

Time frame:
During 26 weeks of treatment
Reported as:
Number · number of events
Incidence of Treatment Emergent Adverse Events (TEAEs)
number of eventsIDegAsp BID + IAsp ODIDeg OD + IAsp TID
Incidence of Treatment Emergent Adverse Events (TEAEs)3345
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes

Confirmed hypoglycaemic episodes were defined as episodes that are either: * severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or * biochemically confirmed by a PG value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.

Time frame:
During 26 weeks of treatment
Reported as:
Number · episodes
Number of Treatment Emergent Hypoglycaemic Episodes
episodesIDegAsp BID + IAsp ODIDeg OD + IAsp TID
Number of Treatment Emergent Hypoglycaemic Episodes5495
SecondaryNumber of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes

Hypoglycaemic episodes were defined as nocturnal if the time of onset was between 00:01 and 05:59 hours inclusive. Confirmed hypoglycaemic episodes were defined as severe hypoglycaemic episodes and/or a measured PG below 3.1 mmol/L (below 56 mg/dL).

Time frame:
During 26 weeks of treatment
Reported as:
Number · episodes
Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes
episodesIDegAsp BID + IAsp ODIDeg OD + IAsp TID
Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes1312
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline in FPG after 26 weeks of treatment. FPG was analysed on blood samples from fasting subjects which were analysed centrally.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LIDegAsp BID + IAsp ODIDeg OD + IAsp TID
Change From Baseline in Fasting Plasma Glucose (FPG)-0.80 ± 3.59-2.57 ± 2.73

Adverse events

Collected over Adverse events were captured on the onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg OD + IAsp TID—2/20 (10%)16/20 (80%)
IDegAsp BID + IAsp OD—2/20 (10%)15/20 (75%)
Most frequent serious events
Most frequent serious events
EventIDeg OD + IAsp TIDIDegAsp BID + IAsp OD
Atrial fibrillationCardiac disorders0/201/20
Peptic ulcer haemorrhageGastrointestinal disorders1/200/20
Cerebrovascular accidentNervous system disorders1/200/20
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/201/20
CholecystectomySurgical and medical procedures1/200/20
Most frequent other events
Showing 10 of 46
Most frequent other events
EventIDeg OD + IAsp TIDIDegAsp BID + IAsp OD
Upper respiratory tract infectionInfections and infestations5/201/20
PyrexiaGeneral disorders4/201/20
Diabetic retinopathyEye disorders0/203/20
Abdominal pain upperGastrointestinal disorders2/201/20
FatigueGeneral disorders0/202/20
Oedema peripheralGeneral disorders0/202/20
CoughRespiratory, thoracic and mediastinal disorders2/201/20
LymphadenopathyBlood and lymphatic system disorders1/200/20
CataractEye disorders0/201/20
Eye swellingEye disorders1/200/20

Baseline characteristics

Full analysis set (FAS) included all randomised subjects.

Age, Continuous
Age, Continuous(years)IDegAsp BID + IAsp ODIDeg OD + IAsp TIDTotal
Mean58.0 ± 8.056.9 ± 8.157.5 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)IDegAsp BID + IAsp ODIDeg OD + IAsp TIDTotal
Female5914
Male151126
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegAsp BID + IAsp ODIDeg OD + IAsp TIDTotal
Mean7.9 ± 0.77.7 ± 0.67.8 ± 0.7
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDegAsp BID + IAsp ODIDeg OD + IAsp TIDTotal
Mean7.3 ± 3.58.6 ± 2.87.9 ± 3.2
09

Study locations

40 sites
  • Novo Nordisk Investigational Site
    Goodyear, Arizona 85395, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85020, United States
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    Spring Valley, California 91978, United States
  • Novo Nordisk Investigational Site
    Bradenton, Florida 34201, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Plantation, Florida 33324, United States
  • Novo Nordisk Investigational Site
    Avon, Illinois 46123, United States
  • Novo Nordisk Investigational Site
    Crystal Lake, Illinois 60012, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46254, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    Waltham, Massachusetts 02453, United States
  • Novo Nordisk Investigational Site
    Buckley, Michigan 49620, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08755-8050, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Myrtle Beach, South Carolina 29572, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75251, United States
  • Novo Nordisk Investigational Site
    Fort Worth, Texas 76132, United States
  • Novo Nordisk Investigational Site
    Olympia, Washington 98502, United States
  • Novo Nordisk Investigational Site
    Tacoma, Washington 98405, United States
  • Novo Nordisk Investigational Site
    Kenosha, Wisconsin 53142, United States
  • Novo Nordisk Investigational Site
    Algiers, 16000, Algeria
  • Novo Nordisk Investigational Site
    Oran, 31000, Algeria
  • Novo Nordisk Investigational Site
    Tizi Ouzou, 16015, Algeria
  • Novo Nordisk Investigational Site
    Erdmannhausen, 71729, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Neuwied, 56564, Germany
  • Novo Nordisk Investigational Site
    Rehlingen-Siersburg, 66780, Germany
  • Novo Nordisk Investigational Site
    St. Ingbert, 66386, Germany
  • Novo Nordisk Investigational Site
    Kota Bharu, Kelantan, 16150, Malaysia
  • Novo Nordisk Investigational Site
    Selangor, 46150, Malaysia
  • Novo Nordisk Investigational Site
    Denizli, 20070, Turkey
  • Novo Nordisk Investigational Site
    Gaziantep, 27070, Turkey
  • Novo Nordisk Investigational Site
    Hatay, 31040, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34752, Turkey
10

References and documents

Publications

  • Bebakar WM, Chaykin L, Herslov ML, Rasmussen S. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes. Diabetes Ther. 2017 Feb;8(1):197-205. doi: 10.1007/s13300-016-0213-8. Epub 2016 Nov 16. PubMed 27853981 ↗
  • Yang W, Akhtar S, Franek E, Haluzik M, Hirose T, Kalyanam B, Kar S, Wu T, Gogas Yavuz D, Unnikrishnan AG. Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. Diabetes Ther. 2022 Feb;13(2):311-323. doi: 10.1007/s13300-021-01196-7. Epub 2022 Jan 19. PubMed 35044568 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 8 months after primary completion. A results delay was requested in Nov 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2013
First posted
Mar 19, 2013
Start
Mar 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results delay requested
Nov 20, 2014
Results first posted
Nov 13, 2015
Last update
Mar 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01814137
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 19, 2013
Start date
Mar 2013
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Nov 13, 2015
Last update
Mar 21, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion